Functional characterization of CFI-400945, a polo-like kinase 4 inhibitor, as a potential anticancer agent

Cancer Cell

Volumn 26, Issue 2, 2014, Pages 163-176

  Mason, JacquelineM ^a   Lin, DanChi Chia ^a   Wei, Xin ^a   Che, Yi ^a   Yao, Yi ^a   Kiarash, Reza ^a   Cescon, David W ^a   Fletcher, Graham C ^a   Awrey, Donald E ^a   Bray, Mark R ^a   Pan, Guohua ^a,b   Mak, Tak W ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CFI 400945; LIPID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLO LIKE KINASE INHIBITOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL DEATH; CHEMICAL STRUCTURE; CLINICAL EVALUATION; CONTROLLED STUDY; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MITOSIS; PRIORITY JOURNAL; SPINDLE POLE; TUMOR XENOGRAFT; WILD TYPE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CENTRIOLES; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDAZOLES; INDOLES; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; PROTEIN-SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905709109     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.05.006     Document Type: Article

References (48)

1. Bassi C., Ho J., Srikumar T., Dowling R.J., Gorrini C., Miller S.J., Mak T.W., Neel B.G., Raught B., Stambolic V. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013, 341:395-399.
2. Basto R., Brunk K., Vinadogrova T., Peel N., Franz A., Khodjakov A., Raff J.W. Centrosome amplification can initiate tumorigenesis in flies. Cell 2008, 133:1032-1042.
3. Bettencourt-Dias M., Rodrigues-Martins A., Carpenter L., Riparbelli M., Lehmann L., Gatt M.K., Carmo N., Balloux F., Callaini G., Glover D.M. SAK/PLK4 is required for centriole duplication and flagella development. Curr. Biol. 2005, 15:2199-2207.
4. Bose S., Crane A., Hibshoosh H., Mansukhani M., Sandweis L., Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum. Pathol. 2002, 33:405-409.
5. Brough R., Frankum J.R., Sims D., Mackay A., Mendes-Pereira A.M., Bajrami I., Costa-Cabral S., Rafiq R., Ahmad A.S., Cerone M.A., et al. Functional viability profiles of breast cancer. Cancer Discov 2011, 1:260-273.
6. Brownlee C.W., Klebba J.E., Buster D.W., Rogers G.C. The Protein phosphatase 2A regulatory subunit twins stabilizes Plk4 to induce centriole amplification. J.Cell Biol. 2011, 195:231-243.
7. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
8. Chng W.J., Braggio E., Mulligan G., Bryant B., Remstein E., Valdez R., Dogan A., Fonseca R. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008, 111:1603-1609.
9. Degenhardt Y., Greshock J., Laquerre S., Gilmartin A.G., Jing J., Richter M., Zhang X., Bleam M., Halsey W., Hughes A., Moy C., Liu-Sullivan N., Powers S., Bachman K., Jackson J., Weber B., Wooster R. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol. Cancer Ther. 2010, 9:2079-2089.
10. Depowski P.L., Rosenthal S.I., Ross J.S. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Pathol. 2001, 14:672-676.
11. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
12. Ganem N.J., Godinho S.A., Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009, 460:278-282.
13. Glaser K.B., Li J., Marcotte P.A., Magoc T.J., Guo J., Reuter D.R., Tapang P., Wei R.-Q., Pease L.J., Bui M.H., et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J.Pharmacol. Exp. Ther. 2012, 343:617-627.
14. Guderian G., Westendorf J., Uldschmid A., Nigg E.A. Plk4 trans-autophosphorylation regulates centriole number by controlling betaTrCP-mediated degradation. J.Cell Sci. 2010, 123:2163-2169.
15. Gully C.P., Zhang F., Chen J., Yeung J.A., Velazquez-Torres G., Wang E., Yeung S.C., Lee M.H. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol. Cancer 2010, 9:42.
16. Habedanck R., Stierhof Y.D., Wilkinson C.J., Nigg E.A. The Polo kinase Plk4 functions in centriole duplication. Nat. Cell Biol. 2005, 7:1140-1146.
17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
18. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth invivo. Nat. Med. 2004, 10:262-267.
19. Holland A.J., Lan W., Niessen S., Hoover H., Cleveland D.W. Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability. J.Cell Biol. 2010, 188:191-198.
20. Holland A.J., Fachinetti D., Zhu Q., Bauer M., Verma I.M., Nigg E.A., Cleveland D.W. The autoregulated instability of Polo-like kinase 4 limits centrosome duplication to once per cell cycle. Genes Dev. 2012, 26:2684-2689.
21. Hook K.E., Garza S.J., Lira M.E., Ching K.A., Lee N.V., Cao J., Yuan J., Ye J., Ozeck M., Shi S.T., et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol. Cancer Ther. 2012, 11:710-719.
22. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
23. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
24. Kleylein-Sohn J., Westendorf J., Le Clech M., Habedanck R., Stierhof Y.D., Nigg E.A. Plk4-induced centriole biogenesis in human cells. Dev. Cell 2007, 13:190-202.
25. Ko M.A., Rosario C.O., Hudson J.W., Kulkarni S., Pollett A., Dennis J.W., Swallow C.J. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat. Genet. 2005, 37:883-888.
26. Li J., Tan M., Li L., Pamarthy D., Lawrence T.S., Sun Y. SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia 2005, 7:312-323.
27. Liu L., Zhang C.Z., Cai M., Fu J., Chen G.G., Yun J. Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS ONE 2012, 7:e41293.
28. Macmillan J.C., Hudson J.W., Bull S., Dennis J.W., Swallow C.J. Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann. Surg. Oncol. 2001, 8:729-740.
29. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005, 102:13550-13555.
30. Nakagawara A., Arima M., Azar C.G., Scavarda N.J., Brodeur G.M. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 1992, 52:1364-1368.
31. Nakagawara A., Azar C.G., Scavarda N.J., Brodeur G.M. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol. Cell. Biol. 1994, 14:759-767.
32. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
33. Peel N., Stevens N.R., Basto R., Raff J.W. Overexpressing centriole-replication proteins invivo induces centriole overduplication and de novo formation. Curr. Biol. 2007, 17:834-843.
34. Perren A., Weng L.P., Boag A.H., Ziebold U., Thakore K., Dahia P.L., Komminoth P., Lees J.A., Mulligan L.M., Mutter G.L., Eng C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 1999, 155:1253-1260.
35. Peters K.G., Coogan A., Berry D., Marks J., Iglehart J.D., Kontos C.D., Rao P., Sankar S., Trogan E. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumor angiogenesis. Br. J. Cancer 1998, 77:51-56.
36. Puc J., Keniry M., Li H.S., Pandita T.K., Choudhury A.D., Memeo L., Mansukhani M., Murty V.V., Gaciong Z., Meek S.E., et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005, 7:193-204.
37. Puklowski A., Homsi Y., Keller D., May M., Chauhan S., Kossatz U., Grünwald V., Kubicka S., Pich A., Manns M.P., et al. The SCF-FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets HsSAS-6 to control centrosome duplication. Nat. Cell Biol. 2011, 13:1004-1009.
38. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
39. Saal L.H., Gruvberger-Saal S.K., Persson C., Lövgren K., Jumppanen M., Staaf J., Jönsson G., Pires M.M., Maurer M., Holm K., et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat. Genet. 2008, 40:102-107.
40. Salvatore G., Nappi T.C., Salerno P., Jiang Y., Garbi C., Ugolini C., Miccoli P., Basolo F., Castellone M.D., Cirafici A.M., et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res. 2007, 67:10148-10158.
41. Sampson, P.B., Liu, Y., Li, S.-W., Forrest, B.T., Pauls, H.W., Edwards, L.G., Feher, M., Patel, N., and Laufer, R. Kinase inhibitors and method of treating cancer. U.S. Patent, 8263596, B2, September 11, 2012.
42. Sampson P.B., Liu Y., Patel N., Feher M., Forrest B., Li S.-W., Edwards L.G., Laufer R., Lang Y., Ban F., et al. The discovery of Polo-like kinase 4 inhibitors: design and optimization of Spiro[cyclopropane-1,3'[3H]indol]-2'(1'H)-ones as orally bioavailable antitumor agents. J.Med. Chem. 2014, Published online May 27, 2014. 10.1021/jm500537u.
43. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., Turashvili G., Ding J., Tse K., Haffari G., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
44. Sillibourne J.E., Tack F., Vloemans N., Boeckx A., Thambirajah S., Bonnet P., Ramaekers F.C., Bornens M., Grand-Perret T. Autophosphorylation of polo-like kinase 4 and its role in centriole duplication. Mol. Biol. Cell 2010, 21:547-561.
45. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N.Engl. J. Med. 2002, 347:1999-2009.
46. Wasielewski M., Elstrodt F., Klijn J.G., Berns E.M., Schutte M. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Breast Cancer Res. Treat. 2006, 99:97-101.
47. Wooster R., Weber B.L. Breast and ovarian cancer. N.Engl. J. Med. 2003, 348:2339-2347.
48. * score, and t statistic for hit selection in RNAi high-throughput screens. J.Biomol. Screen. 2011, 16:775-785.